14-day Premium Trial Subscription Sign Up For FreeGet Free

Catalyst Pharmaceuticals Stock Forecast NASDAQ:CPRX

Price Target and Analyst Ratings

Most Recent Rating

On September 14, 2021 "HC Wainwright" gave "$9.00" rating for CPRX. The price target was changed from $4.98 to 0.2%.

Last 30 Days

Historical Ratings

Date Rating Action Authority Current Price Target Price
2021-09-14 $9.00 Reiterated by HC Wainwright $4.90 $4.98→0.2%
2021-08-10 $5.50 - $6.50 Target Raised by Piper Sandler $5.94 $5.95+3.3%
2021-05-12 Target Raised by Cantor Fitzgerald $4.86 $8.00 → $11.00
2021-03-24 Buy Target Raised by Roth Capital $4.29 $6.50 → $7.00
2021-03-18 Buy Target Raised by Roth Capital $4.21 $6.50 → $7.00
2020-11-10 Overweight Target Lowered by Piper Sandler $3.40 $6.00 → $5.50
2020-08-11 Target Lowered by Piper Sandler $3.34 $7.00 → $6.00
2020-08-04 Buy Reiterated by Oppenheimer $4.13 $8.00
2020-05-13 Buy Target Lowered by SunTrust Banks $4.39 $11.00 → $10.00

CPRX Stock Trend

The stock lies in the lower of a wide and falling trend in the short term, and this may normally pose a very good buying opportunity. If the lower trend floor at $4.88 is broken, it will firstly indicate a stronger fall rate.

Given the current short-term trend, the stock is expected to fall -8.67% during the next 3 months and, with a 90% probability hold a price between $4.46 and $5.33 at the end of this 3-month period.

Data

Date Bottom Mid Top
2021-09-20 $4.87 $5.35 $5.83
2021-09-21 $4.86 $5.34 $5.82
2021-09-22 $4.86 $5.33 $5.81
2021-09-23 $4.85 $5.32 $5.80
2021-09-24 $4.84 $5.32 $5.79
2021-09-27 $4.83 $5.31 $5.78
2021-09-28 $4.82 $5.30 $5.78
2021-09-29 $4.81 $5.29 $5.77
2021-09-30 $4.80 $5.28 $5.76
2021-10-01 $4.79 $5.27 $5.75
2021-10-04 $4.79 $5.26 $5.74
2021-10-05 $4.78 $5.25 $5.73
2021-10-06 $4.77 $5.25 $5.72
2021-10-07 $4.76 $5.24 $5.71
2021-10-08 $4.75 $5.23 $5.71
2021-10-11 $4.74 $5.22 $5.70
2021-10-12 $4.73 $5.21 $5.69
2021-10-13 $4.72 $5.20 $5.68
2021-10-14 $4.72 $5.19 $5.67
2021-10-15 $4.71 $5.18 $5.66
2021-10-18 $4.70 $5.18 $5.65
2021-10-19 $4.69 $5.17 $5.64
2021-10-20 $4.68 $5.16 $5.64
2021-10-21 $4.67 $5.15 $5.63
2021-10-22 $4.66 $5.14 $5.62
2021-10-25 $4.65 $5.13 $5.61
2021-10-26 $4.64 $5.12 $5.60
2021-10-27 $4.64 $5.11 $5.59
2021-10-28 $4.63 $5.10 $5.58
2021-10-29 $4.62 $5.10 $5.57

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies for people with rare debilitating diseases. Its lead product candidate is Firdapse, a proprietary form of amifampridine phosphate, which completed Phase III clinical trial for the treatment of patients with Lambert-Eaton Myasthenic syndrome; and is in small blinded clinical trial to treat Congenital Myasthenic syndromes, as w... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 95.000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT